When You Change the Endpoint at Month 12: What CHOICE-2 Got Right About Amendment Governance
CHOICE-2 changed its primary endpoint after 283 enrollments with no interim data released. Here's what that timeline reveals about...
CHOICE-2 changed its primary endpoint after 283 enrollments with no interim data released. Here's what that timeline reveals about...
The Lancet calls out "hard to reach" as a stigmatizing label. For clinical ops, it's a site selection failure...
Six AI models picked the same "random" number. Clinical ops leaders are finally asking what that reveals about every...
Merck and SCRI's Accelero™ collaboration targets community oncology enrollment, but the real test is whether 200+ sites can execute...
Curavit's acquisition of Lindus Health CRO assets combines 1,000+ global sites with DCT infrastructure—but site teams absorb the operational...
Scholar Rock's BLA refiling for SMA drug apitegromab after Catalent Indiana's OAI classification shows how CMO inspection failures translate...
Caidya and Simbec-Orion's June 2026 merger creates real site-level friction: dual CTMS logins, monitoring model gaps, and budget renegotiations...
Sponsors treat CRO contract signing as a handoff. Three independent clinical ops leaders say that abdication, not bad molecules,...
A leading sponsor hit 79% site adoption and called it a ceiling. The fix isn’t better tools—it’s pre-protocol invariants...
Tevogen Bio's MSO/CRO acquisition push signals a consolidation wave that will disrupt site activation, monitoring, and contracts mid-study. Here's...